Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
SURITAL vs ABILIFY
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
SURITAL (thiamylal) is an ultra-short-acting barbiturate that enhances GABA-A receptor activity, increasing chloride ion conductance and neuronal hyperpolarization, resulting in rapid induction of anesthesia.
Partial agonist at dopamine D2 and serotonin 5-HT1A receptors; antagonist at serotonin 5-HT2A receptors.
Induction of anesthesia,Maintenance of anesthesia as part of balanced anesthesia,Adjunct to regional anesthesia,Control of convulsive states (off-label)
Schizophrenia,Bipolar I disorder (acute manic/mixed episodes, maintenance),Major depressive disorder (adjunctive therapy),Irritability associated with autistic disorder,Tourette's disorder
Induction: 3-5 mg/kg IV bolus over 10-15 seconds. Maintenance: 0.5-1.5 mg/kg IV as needed for anesthesia. Also used as 0.2-0.4% solution for IV infusion at 0.5-2 mg/min.
Schizophrenia: 10-15 mg once daily (max 30 mg). Bipolar mania: 15-30 mg once daily (as monotherapy or adjunct). Adjunctive MDD: 2-5 mg once daily, titrating to 5-10 mg. Autism irritability: 2 mg/day initially, titrated to 5-10 mg/day (max 15 mg/day).
Terminal elimination half-life 2-8 hours (mean 4.5 h) in adults; prolonged in hepatic impairment.
Aripiprazole: 75 hours; dehydro-aripiprazole: 94 hours. Steady-state reached in ~14 days.
Primarily hepatic metabolism via microsomal enzyme oxidation (CYP2B6, CYP3A4) to inactive metabolites; minor renal excretion.
Hepatic metabolism primarily via CYP3A4 and CYP2D6; also by dehydrogenation and N-dealkylation.
Primarily renal excretion of metabolites; <1% unchanged. Minor biliary/fecal elimination.
Renal (25% unchanged, 18% as dehydro-aripiprazole) and fecal (55% unchanged and metabolites).
~70% bound to albumin.
>99% bound to albumin and alpha-1-acid glycoprotein.
1.5-2.5 L/kg; indicates extensive tissue distribution.
4.9 L/kg (high distribution into tissues).
IM: ~90%.
Oral: 87% (tablet and solution); IM: 100%.
No specific GFR-based adjustments; metabolized primarily in liver. Caution in severe renal impairment due to potential accumulation of inactive metabolites.
No dosage adjustment required for renal impairment; not removed by hemodialysis.
Child-Pugh A: No adjustment. Child-Pugh B: Reduce dose by 50% and titrate to effect. Child-Pugh C: Contraindicated or use with extreme caution with reduced doses (e.g., 25-50% of normal).
No specific guidelines; use caution in severe hepatic impairment (Child-Pugh class C) due to limited data.
Induction: 3-6 mg/kg IV. Maintenance: 1-2 mg/kg IV as needed. Use with caution; not recommended for neonates.
Schizophrenia (13-17 years): 2 mg/day, target 10-25 mg/day. Bipolar mania (10-17 years): 2 mg/day, target 10-30 mg/day. Autism irritability (6-17 years): 2 mg/day, target 5-15 mg/day.
Reduce dose by 30-50% due to decreased clearance and increased sensitivity. Administer slowly and titrate to effect.
Initiate at lower doses (e.g., 2-5 mg/day) and titrate slowly due to increased risk of adverse effects, especially orthostatic hypotension and cognitive decline.
WARNING: RESPIRATORY DEPRESSION AND CARDIAC ARREST. SURITAL may cause severe respiratory depression or apnea, especially with rapid administration. Resuscitative equipment and personnel trained in airway management must be immediately available. Avoid intra-arterial injection due to risk of arteriospasm, thrombosis, and gangrene.
Increased risk of death in elderly patients with dementia-related psychosis due to cerebrovascular events.
Monitor respiratory and cardiac function continuously; use with caution in patients with respiratory compromise, hypotension, shock, or hepatic/renal impairment; may cause laryngospasm, bronchospasm, or hypotension; avoid extravasation; use with caution in porphyria.
Increased mortality in elderly dementia patients, suicidal thoughts/behaviors, neuroleptic malignant syndrome, tardive dyskinesia, metabolic changes (hyperglycemia, dyslipidemia, weight gain), orthostatic hypotension, leukopenia/neutropenia, seizures, body temperature dysregulation, dysphagia, impulse control disorders.
Absolute: Known hypersensitivity to barbiturates, acute intermittent porphyria, severe respiratory insufficiency, status asthmaticus, and conditions where general anesthesia is contraindicated.
Known hypersensitivity to aripiprazole or any of its excipients.
No specific food interactions reported for Surital (thiamylal). However, patients should avoid consuming grapefruit or grapefruit juice for 24 hours before and after administration, as it may theoretically inhibit cytochrome P450 metabolism, although significant interactions are not well-documented.
Grapefruit juice may increase aripiprazole exposure; avoid concurrent intake. No other significant food interactions. Alcohol can enhance CNS depression; limit or avoid.
Pregnancy Category D (positive evidence of human fetal risk). First trimester: Risk of congenital anomalies (limb defects, CNS malformations) based on animal studies and limited human data. Second/third trimester: Increased risk of preterm labor, fetal bradycardia, neonatal respiratory depression, and withdrawal syndrome. Avoid use during pregnancy unless clearly needed.
Pregnancy category C. First trimester: risk of major malformations not significantly increased based on limited data; however, neurodevelopmental effects uncertain. Second and third trimesters: neonates exposed in late pregnancy are at risk for extrapyramidal symptoms (EPS) and withdrawal syndrome including agitation, hypertonia, hypotonia, tremor, somnolence, respiratory distress, feeding disorder.
Excretion into breast milk is unknown; M/P ratio not established. Due to high lipid solubility, potential for significant transfer. Consider risks of neonatal CNS depression. Use with caution; monitor infant for sedation, poor feeding, and respiratory depression. Alternative agents preferred.
Aripiprazole is excreted in human breast milk; milk-to-plasma (M/P) ratio is approximately 0.5 to 1.0. Relative infant dose is estimated to be 1-3% of maternal weight-adjusted dose. Limited data; use with caution. Monitor infant for sedation, poor feeding, and abnormal movements.
Increased volume of distribution and hepatic metabolism in pregnancy may require higher induction doses and more frequent maintenance doses. However, due to fetal risks, avoid use in pregnancy unless absolutely necessary. If used, start at lower range (e.g., 3-4 mg/kg IV induction) and titrate to effect. No established dose adjustment guidelines; individualize based on clinical response and close monitoring.
No established pharmacokinetic data; however, pregnancy-induced physiological changes (increased plasma volume, renal clearance) may lower aripiprazole levels. Monitor therapeutic efficacy and consider dose adjustment if symptom exacerbation. No specific dose modification guidelines available; titrate based on clinical response and tolerability.
Surital (thiamylal) is an ultra-short-acting barbiturate used for induction of anesthesia. Due to its high lipid solubility, onset of action is rapid (<30 seconds). It is contraindicated in porphyria and should be used with caution in patients with hepatic impairment, as it is metabolized in the liver. Extravasation causes tissue necrosis; use a large vein for IV administration. Respiratory depression and laryngospasm are common during induction. Surital has no analgesic properties and may cause myocardial depression at high doses. For short procedures, it provides rapid awakening but with potential residual sedation.
Abilify (aripiprazole) is a partial dopamine agonist, which reduces the risk of extrapyramidal symptoms and hyperprolactinemia compared to full antagonists. Monitor for akathisia, especially during dose titration. QT prolongation risk is lower than with other antipsychotics; use caution in patients with cardiac disease. Avoid use in dementia-related psychosis due to increased mortality. Therapeutic effects may take 2-4 weeks; full response often requires 6-8 weeks.
This medication is used to put you to sleep before surgery or certain procedures.,You may feel dizzy or drowsy for several hours after receiving this drug; do not drive or operate machinery for at least 24 hours.,Avoid alcohol for at least 24 hours after receiving this medication as it can increase side effects.,Inform your healthcare provider if you have a history of porphyria, liver disease, or respiratory problems.,Do not breastfeed for at least 24 hours after administration without consulting your doctor.,Notify your doctor immediately if you experience severe pain, redness, or swelling at the injection site.,You may experience temporary confusion or memory loss after waking up; this is normal and should resolve.
Take exactly as prescribed; do not stop abruptly without consulting your doctor.,May cause drowsiness or dizziness; avoid driving until you know how it affects you.,Avoid alcohol and grapefruit juice as they can alter drug levels.,Report any uncontrolled muscle movements, especially in face or tongue.,Monitor weight and blood glucose regularly as it can cause metabolic changes.,If you miss a dose, take it as soon as you remember unless it's almost time for the next dose; do not double up.,Use effective contraception if of childbearing potential; discuss pregnancy plans with your doctor.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about SURITAL vs ABILIFY, answered by our medical review team.
SURITAL is a Barbiturate Anesthetic that works by SURITAL (thiamylal) is an ultra-short-acting barbiturate that enhances GABA-A receptor activity, increasing chloride ion conductance and neuronal hyperpolarization, resulting in rapid induction of anesthesia.. ABILIFY is a Atypical antipsychotic that works by Partial agonist at dopamine D2 and serotonin 5-HT1A receptors; antagonist at serotonin 5-HT2A receptors.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between SURITAL and ABILIFY depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of SURITAL is: Induction: 3-5 mg/kg IV bolus over 10-15 seconds. Maintenance: 0.5-1.5 mg/kg IV as needed for anesthesia. Also used as 0.2-0.4% solution for IV infusion at 0.5-2 mg/min.. The standard adult dose of ABILIFY is: Schizophrenia: 10-15 mg once daily (max 30 mg). Bipolar mania: 15-30 mg once daily (as monotherapy or adjunct). Adjunctive MDD: 2-5 mg once daily, titrating to 5-10 mg. Autism irritability: 2 mg/day initially, titrated to 5-10 mg/day (max 15 mg/day).. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between SURITAL and ABILIFY in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. SURITAL is classified as Category C. Pregnancy Category D (positive evidence of human fetal risk). First trimester: Risk of congenital anomalies (limb defects, CNS malformations) based on animal studies and limited hu. ABILIFY is classified as Category C. Pregnancy category C. First trimester: risk of major malformations not significantly increased based on limited data; however, neurodevelopmental effects uncertain. Second and thir. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.